Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 8.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,679 shares of the life sciences company’s stock after buying an additional 449 shares during the period. Kestra Private Wealth Services LLC’s holdings in Illumina were worth $759,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Golden State Wealth Management LLC acquired a new position in shares of Illumina during the fourth quarter worth about $32,000. Versant Capital Management Inc increased its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the period. TD Private Client Wealth LLC lifted its holdings in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares during the period. Spire Wealth Management boosted its stake in shares of Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after buying an additional 97 shares in the last quarter. Finally, Private Trust Co. NA grew its holdings in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

ILMN stock opened at $100.24 on Friday. The stock has a market capitalization of $15.90 billion, a price-to-earnings ratio of -13.05 and a beta of 1.10. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52-week low of $99.35 and a 52-week high of $156.66. The stock’s fifty day simple moving average is $133.56 and its 200-day simple moving average is $134.88.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Equities research analysts expect that Illumina, Inc. will post 4.42 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ILMN shares. Stephens raised their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and decreased their price objective for the stock from $130.00 to $100.00 in a report on Monday, February 10th. Piper Sandler increased their target price on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Guggenheim decreased their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, UBS Group raised their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.